# US 2012/0255047 A1 · Porcine Animals Lacking Any Expression of Functional Alpha 1,3 Galactosyltransferase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0255047 A1
- Document ID: US20120255047A1
- Status: Published application
- Kind: A1
- Application number: 12/835,026
- Filed: 2010-07-13
- Published: 2012-10-04
- Earliest claimed: 2002-08-21
- Inventors: Carol J. Phelps; David L. Ayares
- Web page: https://patentgrep.com/patent/US20120255047A1

## CPC

- A01K 67/0276: Knock-out vertebrates
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 9/2465: {acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)}
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/108: Swine
- A01K 2267/02: Animal zootechnically ameliorated
- A01K 2267/025: Animal producing cells or organs for transplantation
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention is a porcine animal, tissue, organ, cells and cell lines, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha1,3GT). These animals, tissues, organs and cells can be used in xenotransplantation and for other medical purposes.

## Claims

### Claim 1

A pig that lacks any expression of functional alpha1,3 galactosyltransferase.

### Claim 2

An organ of a pig that lacks any expression of functional alpha1,3 galactosyltransferase.

### Claim 3 (depends on 2)

The organ of claim 2, wherein the organ is a kidney.

### Claim 4 (depends on 2)

The organ of claim 2, wherein the organ is a liver.

### Claim 5 (depends on 2)

The organ of claim 2, wherein the organ is a heart.

### Claim 6 (depends on 2)

The organ of claim 2, wherein the organ is a lung.

### Claim 7 (depends on 2)

The organ of claim 2, wherein the organ is a pancreas.

### Claim 8

A tissue of a pig that lacks any expression of functional alpha1,3 galactosyltransferase.

### Claim 9 (depends on 8)

The tissue of claim 8, wherein the tissue is cartilage.

### Claim 10 (depends on 8)

The tissue of claim 8, wherein the tissue is bone.

### Claim 11 (depends on 8)

The tissue of claim 8, wherein the tissue is adipose.

### Claim 12 (depends on 8)

The tissue of claim 8, wherein the tissue is muscle.

### Claim 13

A cell or a cell line from a pig that lacks any expression of functional alpha1,3 galactosyltransferase.

### Claim 14 (depends on 13)

The cell of claim 13, wherein the cell is derived from the pancreas.

### Claim 15 (depends on 14)

The cell of claim 14, wherein the cell is an Islet of Langerhans cell.

### Claim 16 (depends on 14)

The cell of claim 14, wherein the cell is an insulin secreting cell.

### Claim 17

A method for the production of a pig that lacks any expression of functional alpha1,3 galactosyltransferase comprising: breeding a male pig heterozygous for the alpha-1,3-GT gene with a female pig heterozygous for the alpha-1,3-GT gene.

### Claim 18 (depends on 17)

The method of claim 17, wherein one or both pigs are heterozygous due to the genetic modification of one allele of the alpha-1,3-GT gene to prevent expression of that allele.

### Claim 19 (depends on 17)

The method of claim 17, wherein one or both pigs are heterozygous due to the presence of a point mutation in an allele of the alpha-1,3-GT gene.

### Claim 20 (depends on 19)

The method of claim 19, wherein the point mutation is a T-to-G point mutation at the second base of exon 9 of the alpha-1,3-GT gene.

### Claim 21 (depends on 17)

The method of claim 17, wherein a male pig that contains a T-to-G point mutation at the second base of exon 9 of the alpha-1,3-GT gene is bred with a female pig that contains a T-to-G point mutation at the second base of exon 9 of the alpha-1,3-GT gene.

### Claim 22

A method for producing an alpha 1,3 GT deficient non-human animal comprising:
(a) exposing a population of cells to C. difficile toxin A;
(b) removing cells which lift from the surface matrix because they are adversely affected by toxin A due to the receptor-mediated cytotoxicity of the toxin;
(c) expanding and maintaining those cells which do not show the effects of receptor-mediated cytotoxicity;
(d) using these toxin A-resistant cells as nuclear donors for nuclear transplantation into a suitable recipient cell;
(e) implanting the fused and activated cells into a female surrogate; and
(f) producing a cloned animal which exhibits a deficiency or complete lack of gal alpha1,3-gal epitopes on its cell surfaces.

### Claim 23 (depends on 22)

The method of claim 22, wherein the cells to be selected for have been rendered heterozygous with respect to the gal alpha1,3 allele, via targeted knockout of one allele by homologous recombination.

### Claim 24 (depends on 22)

The method of claim 22, wherein the cells to be selected for have been rendered homozygous with respect to the gal alpha1,3 allele, via targeted knockout of both alleles by homologous recombination.

### Claim 25 (depends on 22)

The method of claim 22 wherein the cells to be selected for have been rendered heterozygous with respect to the gal alpha1,3 allele via a natural mutation of a single gal alpha1,3 allele, which disables the alpha 1,3 galactosyltransferase gene.

### Claim 26 (depends on 22)

The method of claim 22 wherein the cells to be selected carry an alpha 1,3 gal double knockout created by targeted knockout of one allele by homologous recombination and natural mutation of the second allele.

### Claim 27 (depends on 22)

The method of claim 22 wherein the cells to be selected for are homozygous with respect to the gal alpha1,3 allele accomplished via natural mutations of both gal alpha1,3 alleles, which disables the alpha 1,3 galactosyltransferase gene.

### Claim 28 (depends on 22)

The method of claim 22 wherein the cells to be selected for carry an alpha 1,3 gal double knockout accomplished via targeted knockout of one allele by homologous recombination and natural mutation of the second allele which disables the alpha 1,3 galactosyltransferase gene.

### Claim 29 (depends on 22)

The method of claim 22, wherein the cells to be selected for have been rendered homozygous with respect to the gal alpha1,3 allele via induced mutations of both gal alpha1,3 alleles, which disables the alpha 1,3 galactosyltransferase gene.

### Claim 30 (depends on 22)

The method of claim 22 wherein the Clostridium difficile toxin A used for selection is in the form of a purified toxin.

### Claim 31 (depends on 22)

The method of claim 22 wherein the Clostridium difficile toxin A used for selection is in the form of a culture supernatant fluid.

### Claim 32 (depends on 22)

The method of claim 22 wherein the purified toxin is applied to dispersed cells, and wherein said dispersed cells are then cultured in vitro in vessels suitable for cell adherence.

### Claim 33 (depends on 22)

The method of claim 22, wherein the purified toxin is applied to adhered cells.

### Claim 34 (depends on 22)

The method of claim 22, wherein the culture supernatant fluid is applied to dispersed and un-adhered cells followed by culturing in vessels suitable for cell adherence.

### Claim 35 (depends on 22)

The method of claim 22, wherein the culture supernatant fluid is applied

### Claim 36 (depends on 22)

The method of claim 22, wherein said animal is a pig.

### Claim 37 (depends on 22)

The method of claim 22, wherein a mutation is induced by a mutagenic agent selected from the group consisting of a chemical mutagen, radiation, and a transposon.

### Claim 38 (depends on 22)

The method of claim 22, wherein said chemical mutagen is selected from the group consisting of EMS, ENU, mustard gas and ICR191.

### Claim 39 (depends on 22)

The method of claim 22, wherein said radiation is selected from the group consisting of ultraviolet radiation, alpha radiation, beta radiation and gamma radiation.

### Claim 40

A cell that carries a homozygous knockout for the gal alpha-1,3-GT gene in which at least one allele contains a natural or spontaneous mutation in the gal alpha-1,3-GT gene, wherein said cell is produced by a method comprising:
(a) exposing a population of cells to C. difficile toxin A;
(b) removing cells which are adversely affected by toxin A due to the receptor-mediated cytotoxicity of the toxin; and
(c) expanding and maintaining a cell that does not show the effects of receptor-mediated cytotoxicity.

### Claim 41 (depends on 40)

The cell of claim 40, wherein said cell carries a homozygous knockout for the gal alpha-1,3-GT gene in which at least one allele contains the base substitution thymine to guanine at base position 424 of the alpha 1,3 GT gene, resulting in the amino acid substitution tyrosine to aspartic acid at position 142 in the gal alpha-1,3-GT protein.

### Claim 42 (depends on 40)

The cell of claim 40, wherein said cell carries a homozygous knockout for the gal alpha-1,3-GT gene in which at least one allele contains an induced mutation in the gal alpha-1,3-GT gene.

### Claim 43 (depends on 22)

An animal produced according to the method of claim 22.

### Claim 44 (depends on 40)

An animal produced by nuclear transfer cloning using the cell of claim 40 as a nuclear donor.

### Claim 45 (depends on 41)

An animal produced by nuclear transfer cloning using the cell of claim 41 as a nuclear donor.

### Claim 46 (depends on 42)

An animal produced by nuclear transfer cloning using the cell of claim 42 as a nuclear donor.

### Claim 47 (depends on 42)

Cells, tissues, and organs obtained from the animal of claim 42 for use as an in vivo or ex vivo supplement or replacement for recipient cells, tissues or organs.

### Claim 48 (depends on 43)

Cells, tissues, and organs obtained from the animal of claim 43 for use as an in vivo or ex vivo supplement or replacement for recipient cells, tissues, or organs.

### Claim 49 (depends on 44)

Cells, tissues, and organs obtained from the animal of claim 44 for use as an in vivo or ex vivo supplement or replacement for recipient cells, tissues, or organs.

### Claim 50 (depends on 45)

Cells, tissues, and organs obtained from the animal of claim 45 for use as an in vivo or ex vivo supplement or replacement for recipient cells, tissues, or organs.
